DUAL CHECKPOINT ABROGATION IS SYNERGISTIC IN KRAS-MUTANT CANCER

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2015年 / 5卷 / 09期
关键词：
D O I：
10.1158/2159-8290.CD-RW2015-133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：903 / 903
页数：1
相关论文
共 50 条
  • [31] An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
    Koichi Tomoshige
    Minzhe Guo
    Tomoshi Tsuchiya
    Takuya Fukazawa
    Iris M. Fink-Baldauf
    William D. Stuart
    Yoshio Naomoto
    Takeshi Nagayasu
    Yutaka Maeda
    Oncogene, 2018, 37 : 3894 - 3908
  • [32] Utility of a selective SHP2-inhibitor in KRAS-mutant cancer
    Hao, H.
    Wang, H.
    Liu, C.
    Kovats, S.
    Velazquez, R.
    Lu, H.
    Pant, B.
    Lim, J.
    Fleming, M.
    Shirley, M.
    Lamarche, M.
    Moody, S.
    Silver-Brown, S.
    Caponigro, G.
    Abrams, T.
    Hammerman, P.
    Williams, J.
    Engelman, J.
    Goldoni, S.
    Mohseni, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E24 - E24
  • [33] Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
    Jieqiong Wang
    Kewen Hu
    Jiawei Guo
    Feixiong Cheng
    Jing Lv
    Wenhao Jiang
    Weiqiang Lu
    Jinsong Liu
    Xiufeng Pang
    Mingyao Liu
    Nature Communications, 7
  • [34] A pan-KRAS degrader for the treatment of KRAS-mutant cancers
    Yang, Jie
    Wang, Qiao-Li
    Wang, Guan-Nan
    Ye, Jia-Cong
    Li, Zi-Qian
    Wang, Jing-Yun
    Liang, Zhao-Hui
    Li, Shu-Xin
    Sun, Cong
    Liao, Wen-Ting
    Gao, Yi-Jun
    Wang, Jing
    Mao, Yong
    Yu, Chunjing
    Feng, Guo-Kai
    Zeng, Mu-Sheng
    CELL DISCOVERY, 2024, 10 (01)
  • [35] Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
    Klomp, Jennifer E.
    Diehl, J. Nathaniel
    Klomp, Jeffrey A.
    Edwards, A. Cole
    Yang, Runying
    Morales, Alexis J.
    Taylor, Khalilah E.
    Drizyte-Miller, Kristina
    Bryant, Kirsten L.
    Schaefer, Antje
    Johnson, Jared L.
    Huntsman, Emily M.
    Yaron, Tomer M.
    Pierobon, Mariaelena
    Baldelli, Elisa
    Prevatte, Alex W.
    Barker, Natalie K.
    Herring, Laura E.
    Petricoin III, Emanuel F.
    Graves, Lee M.
    Cantley, Lewis C.
    Cox, Adrienne D.
    Der, Channing J.
    Stalnecker, Clint A.
    SCIENCE, 2024, 384 (6700) : eadk0850
  • [36] Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer
    Yang, Zhang
    Liang, Shun-Qing
    Saliakoura, Maria
    Yang, Haitang
    Vassella, Eric
    Konstantinidou, Georgia
    Tschan, Mario
    Hegedus, Balazs
    Zhao, Liang
    Gao, Yanyun
    Xu, Duo
    Deng, Haibin
    Marti, Thomas M.
    Kocher, Gregor J.
    Wang, Wenxiang
    Schmid, Ralph A.
    Peng, Ren-Wang
    EMBO MOLECULAR MEDICINE, 2021, 13 (09)
  • [37] Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
    Park, Sujeong
    Oh, Jinjoo
    Kim, Minhee
    Jin, Eun-Jung
    ANIMAL CELLS AND SYSTEMS, 2018, 22 (05) : 334 - 340
  • [38] New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
    Yang, Haitang
    Liang, Shun-Qing
    Schmid, Ralph A.
    Peng, Ren-Wang
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [39] PCSK9 IS A THERAPEUTIC TARGET IN KRAS-MUTANT COLORECTAL CANCER
    Wong, Chi Chun
    Wu, Jianlin
    Chan, Lam-Shing
    Ji, Fenfen
    Kang, Wei
    To, Ka Fai
    Sung, Joseph J.
    Yu, Jun
    GASTROENTEROLOGY, 2021, 160 (06) : S64 - S64
  • [40] Combination inhibitor strategies targeting KRAS effector signaling in KRAS-mutant pancreatic cancer.
    Ozkan-Dagliyan, Irem
    Goodwin, Craig M.
    Bryant, Kirsten L.
    George, Samuel D.
    Lucas, Kelly
    Gautam, Prson
    Wennerberg, Krister
    Cox, Adrienne D.
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 68 - 68
12345